Eli Lilly posted strong earnings as demand for weight loss drugs soared Apr 30, 2026 · Cris Tolomia U.S. sales of Zepbound, Lilly's obesity drug, hit $4.16 billion, an 80% year-over-year gain. Sales of Mounjaro more than doubled Read more »
.jpg?branch=production&format=jpg&width=1024)
.jpg?branch=production&format=jpg&width=1024)
.png?branch=production&format=jpg&width=1024)
